candesartan has been researched along with trandolapril in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jin, D; Miyazaki, M; Shiota, N; Takai, S | 1 |
| Daicho, T; Koshimizu, M; Oikawa, R; Takahashi, M; Takeo, S; Tanonaka, K; Toyo-Oka, T; Yoshida, H | 1 |
| Komuro, I; Kuwabara, Y | 1 |
| Cohen-Solal, A; Dietz, R; Eichhorn, E; Erhardt, L; Hobbs, FD; Krum, H; Maggioni, A; McKelvie, RS; McMurray, J; Piña, IL; Soler-Soler, J; Swedberg, K | 1 |
| Daicho, T; Koshimizu, M; Oikawa, R; Takahashi, M; Takeo, S; Tanonaka, K; Yoshida, H | 1 |
| Kanno, Y; Shoda, J; Suzuki, H | 1 |
| Feng, Y; Huang, R; Li, X; Melgiri, ND; Qin, X; Sun, Y; Wang, Y | 1 |
3 review(s) available for candesartan and trandolapril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Ace inhibitors and angiotensin II receptor antagonists for therapy of chronic heart failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Enalapril; Heart Failure; Humans; Indoles; Lisinopril; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2005 |
Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bayes Theorem; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Follow-Up Studies; Fosinopril; Humans; Hypertension; Indoles; Kidney Diseases; Middle Aged; Patient Safety; Probability; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Young Adult | 2017 |
1 trial(s) available for candesartan and trandolapril
| Article | Year |
|---|---|
A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Chronic Disease; Creatinine; Female; Glomerular Filtration Rate; Glomerulonephritis; Humans; Indoles; Losartan; Male; Middle Aged; Prospective Studies; Renal Insufficiency; Tetrazoles | 2006 |
5 other study(ies) available for candesartan and trandolapril
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Roles of vascular angiotensin converting enzyme and chymase in two-kidney, one clip hypertensive hamsters.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Chymases; Cricetinae; Humans; Hypertension, Renovascular; Indoles; Male; Peptidyl-Dipeptidase A; Renin; Serine Endopeptidases; Tetrazoles | 1998 |
Effects of ACE inhibitor and AT1 blocker on dystrophin-related proteins and calpain in failing heart.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, Western; Calpain; Cytosol; Heart Failure; Hemodynamics; Indoles; Male; Models, Animal; Myocardium; Protein Isoforms; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; Sarcoglycans; Tetrazoles | 2005 |
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzopyrans; Biphenyl Compounds; Bisoprolol; Captopril; Carbazoles; Carvedilol; Drug Therapy, Combination; Enalapril; Ethanolamines; Evidence-Based Medicine; Guideline Adherence; Heart Failure; Humans; Indoles; Lisinopril; Metoprolol; Mineralocorticoid Receptor Antagonists; Nebivolol; Practice Guidelines as Topic; Propanolamines; Ramipril; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan | 2005 |
Effects of angiotensin I-converting enzyme inhibitor and angiotensin II type 1 receptor blocker on the right ventricular sarcoglycans and dystrophin after left coronary artery ligation.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blotting, Western; Body Weight; Calcium-Binding Proteins; Calpain; Coronary Vessels; Cytosol; Dystrophin; Gene Expression; Heart Rate; Heart Ventricles; Indoles; Ligation; Male; Myocardial Infarction; Protein Isoforms; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sarcoglycans; Tetrazoles; Time Factors; Transcription, Genetic | 2005 |